logo
Plus   Neg
Share
Email

Catalyst Biosciences Inc. (CBIO) Has Tumbled To A 6-Month Low

Catalyst Biosciences Inc. (CBIO) provided an update on its Phase 1/2 trial of CB 2679d/ISU304, for the treatment of severe hemophilia B, Monday morning.

Catalyst Biosciences has gapped open sharply lower this morning and is now down 14.29 at $10.96 on above average volume. The stock has plunged to a 6-month low.

For comments and feedback contact: editorial@rttnews.com

Business News

Follow RTT